Arzerra: new leukaemia antibody

GlaxoSmithKline has launched a new biological treatment for chronic lymphocytic leukaemia (CLL).

Ofatumumab (Arzerra) is a fully human monoclonal antibody. Like rituximab, it is specific for the CD20 antigen found on B cells.

Ofatumumab was tested in a pivotal study in 154 patients with CLL, a type of B cell tumour. Among the 59 participants who were refractory to fludarabine and alemtuzumab, 58% responded to ofatumumab treatment. Response rates were comparable between those who had previously received rituximab and those who had not.

Arzerra has been conditionally approved by the European Medicines Agency; therefore, the agency will review any new data on the product annually.

View Arzerra drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Further monthly injectable migraine prophylactic launched

Further monthly injectable migraine prophylactic launched

With the launch of Emgality (galcanezumab), prescribers...

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...